5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
January 2002 in “Dialnet (Universidad de la Rioja)” Finasteride treatment makes the prostate look more like a healthy one.
Combining anastrozole with finasteride may better treat hormone imbalance in BPH.
Combining anastrozole with finasteride may better treat hormone imbalance in BPH.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
August 2016 in “Journal of Investigative Dermatology”
72 citations
,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
February 2017 in “대한피부과학회지” Combining low-dose dutasteride with finasteride improved a man's hair loss.
1 citations
,
September 2024 in “African Journal of Urology” Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
9 citations
,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
7 citations
,
September 1997 in “PubMed”
March 2021 in “Clin-Alert” The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
20 citations
,
May 2018 in “The Journal of Urology” Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
19 citations
,
April 2020 in “Dermatologic Therapy” Dutasteride works better than finasteride for hair loss, with both being safe to use.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
August 2002 in “Inpharma Weekly” 2 citations
,
April 2024 in “Urology Annals” Taking dutasteride every other day works as well as daily and better preserves sexual function.
5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.
1 citations
,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
35 citations
,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
March 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
April 2013 in “The FASEB Journal” Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
December 2003 in “British Journal of Urology”
2 citations
,
October 2021 in “Asian Journal of Andrology” Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
13 citations
,
December 2012 in “Canadian Urological Association Journal” 5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.
3 citations
,
November 2018 in “The Journal of Clinical Psychiatry” Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.